Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
前收盤價
US$17.58
−US$0.96 · -5.18%
盤中時間採用ET。市場資料可能有所延遲。
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
日內區間
目前US$17.58
52週區間
目前US$17.58
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|
| 營收 | 8.12億 USD | 4.12億 USD | 3.06億 USD | 2.58億 USD |
| 銷貨成本 | 2.73億 USD | 2.33億 USD | 2.17億 USD | 1.78億 USD |
| 毛利 | 5.39億 USD | 1.79億 USD | 8931萬 USD | 8002.2萬 USD |
| 研究與開發 | 4531.4萬 USD | 1.14億 USD | 1.17億 USD | 1.01億 USD |
| 銷售、一般及管理費用 | 3.92億 USD | 3.22億 USD | 2.91億 USD | 2.95億 USD |
| 營業費用 | 4.94億 USD | 4.36億 USD | 4.09億 USD | 3.96億 USD |
| 利息收入 | 1649.7萬 USD | 712.2萬 USD | 1125.8萬 USD | 94.7萬 USD |
| 利息支出 | 5685.3萬 USD | 5002.5萬 USD | 3161萬 USD | 2668萬 USD |
| 折舊和攤銷 | 2261.5萬 USD | 4891.3萬 USD | 4900.1萬 USD | 4825.3萬 USD |
| 營業利益 | 4511.3萬 USD | −2.57億 USD | −3.2億 USD | −3.16億 USD |
| 淨利 | −5.38億 USD | −2.82億 USD | −3.41億 USD | −3.21億 USD |
公司資料更新於 2026年11月22日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動,並非 GoAI 建議。
平均目標
US$34.00
上漲空間 93.40%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1.1億0.01%6893億 USD0.03%US$340.02-3.52%
Vanguard Morningstar Small-Cap ETFVB9790.57萬0.05%787億 USD0.03%US$270.68-2.56%
Vanguard Morningstar Small-Cap Growth ETFVBK5479.24萬0.13%225億 USD0.05%US$298.35-3.85%
Vanguard Extended Market ETFVXF4954.82萬0.05%302億 USD0.05%US$211.44-3.21%
iShares Biotechnology ETFIBB1730.51萬0.17%105.27億 USD0.44%US$199.54-2.05%
First Trust Health Care AlphaDEX FundFXH1543.05萬1.38%11.07億 USD0.61%US$128.9-1.20%
Schwab U.S. Small-Cap ETFSCHA1229.25萬0.06%204.47億 USD0.03%US$30.51-2.83%
iShares Russell Mid-Cap Growth ETFIWP1092.53萬0.07%163.65億 USD0.23%US$116.81-4.32%
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Morningstar Small-Cap ETFVB
Vanguard Morningstar Small-Cap Growth ETFVBK
Vanguard Extended Market ETFVXF
iShares Biotechnology ETFIBB
First Trust Health Care AlphaDEX FundFXH
Schwab U.S. Small-Cap ETFSCHA
iShares Russell Mid-Cap Growth ETFIWPAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。